Broadcasting News

47-Year-Old Koyote Member Kim Jong-min Is Going to Be a Dad… His Wife, 11 Years His Junior, Is Pregnant

Married last April Revealed on the set of "Super Dad"

KIM HYUNSIK
2026-10-06 09:25:05
[Edaily Starin KIM HYUNSIK Reporter] Singer and TV personality Kim Jong-min (47), a member of the mixed-gender group Koyote, is set to become a father.
Kim Jong-min (Photo: KBS)
According to the production team of the KBS 2TV parenting variety show “The Return of Superman” (“Superman”) on the 6th, Kim Jong-min announced the news of his wife’s pregnancy during a recent taping.
Kim Jong-min married his wife, who is 11 years his junior, last April. His wife is reportedly a businesswoman.
During the “Superman” recording, Kim Jong-min revealed, “My wife is now 17 weeks pregnant.” He went on to express his joy, saying, “To have a child, I abstained from alcohol for a year and took care of my health. Thanks to that, it seems our baby came to us quickly.”
“Super Dad” airs every Wednesday at 8:30 p.m. The episode featuring host Kim Jong-min announcing the pregnancy will air on the 7th.
The “Super Dad” production team stated, “Please look forward to seeing a new side of Kim Jong-min—who has closely followed the stories of ‘parenting veterans’ through ‘Super Dad’—as he takes on the role of a father-to-be.”

Economy

Corporation

IT·Science

Economy

Japanese Finance Minister Proposes "Combination of Stablecoins, Tokenized Deposits, and Government Bonds"... to Lead a Government-Wide Forum

As the Japanese government moves forward with plans to incorporate crypto assets into the framework of the Financial Instruments and Exchange Act (hereinafter referred to as the FIEA), the government …
2026-11-20 14:30:21

Corporation

curacle co., ltd. Files for U.S. Phase 2b Clinical Trial of CU06, an Oral Treatment for Diabetic Macular Edema

curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
2026-11-20 13:02:02

IT·Science

Aimed Bio Inc.’s ADC Technology Export Shows 60% Response Rate in Phase 1 Clinical Trial… Moving Forward with U.S. Approval Trials

#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…
2026-11-20 13:07:02